Increasing knowledge about signal transduction pathways as drivers of cancer growth has elicited the development of "targeted drugs," which inhibit aberrant signaling pathways. They require a companion diagnostic test that identifies the tumor-driving pathway; however, currently available tests like estrogen receptor (ER) protein expression for hormonal treatment of breast cancer do not reliably predict therapy response, at least in part because they do not adequately assess functional pathway activity. Wedescribe a novel approach to predict signaling pathway activity based on knowledge-based Bayesian computationalmodels,which interpret quantitative transcriptome data as the functional output of an active signaling pathway, by using expression levels of transcriptional target genes. Following calibration on only a small number of cell lines or cohorts of patient data, they provide a reliable assessment of signaling pathway activity in tumors of different tissue origin. As proof of principle, models for the canonical Wnt and ER pathways are presented, including initial clinical validation on independent datasets from various cancer types.

Additional Metadata
Persistent URL dx.doi.org/10.1158/0008-5472.CAN-13-2515, hdl.handle.net/1765/56593
Journal Cancer Research
Citation
Verhaegh, W, van Ooijen, H, Inda, M.A, Hatzis, P, Versteeg, R, Smid, M, … van de Stolpe, A. (2014). Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. Cancer Research, 74(11), 2936–2945. doi:10.1158/0008-5472.CAN-13-2515